Research has found that share of branded drug spending with a coupon increased from 26% to 54% between 2007 and 2010. (Photo: Shutterstock)
A new study has found that drug copayment coupons, while lowering the initial cost to individuals, contribute to higher drug prices overall in the U.S. In one specific category—drugs that treat multiple sclerosis (MS)—the study found that coupons raise negotiated prices by 8% and result in just under $1 billion in increased U.S. pharmaceutical spending annually. The study also estimated that copayment coupons increase spending on couponed drugs without bioequivalent generics by up to 30%.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
